# A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

> **NCT03281681** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **DelMar Pharmaceuticals, Inc.**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** VAL-083, Dianhydrogalactitol

## Key facts

- **NCT ID:** NCT03281681
- **Lead sponsor:** DelMar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03
- **Primary completion:** 2022-03
- **Final completion:** 2022-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Alternate study design for ovarian cancer under discussion
- **Last updated:** 2019-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281681, "A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03281681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*